Genovis Investor Relations » Press Releases

April 25, 2023 15:00 (CEST) Genovis acquires IP Rights to novel enzymes for applications within genomics Regulatory

April 25, 2023 11:15 (CEST) Genovis Annual Report 2022 published Regulatory

April 11, 2023 12:30 (CEST) NOTICE CONVENING THE 2023 ANNUAL GENERAL MEETING Regulatory

February 15, 2023 08:00 (CET) Year-end Report January-December 2022 Regulatory MAR

January 09, 2023 13:57 (CET) Genovis to receive 4 MUSD upfront after Selecta Biosciences sublicensed Xork™ enzyme to Astellas Pharma Regulatory MAR

November 15, 2022 08:00 (CET) Interim Report January-September 2022 Regulatory MAR

August 12, 2022 08:00 (CEST) Half-Year Report for the First Half of 2022 Regulatory MAR

August 10, 2022 14:00 (CEST) Genovis enters licensing and supply agreement with new bioprocess customer Regulatory

August 04, 2022 13:00 (CEST) Genovis AB enters service agreement with evitria AG for fast LC-MS analysis of recombinant antibodies Regulatory

May 12, 2022 11:56 (CEST) Communiqué from Genovis AB (publ) Annual General Meeting May 12, 2022 Regulatory

Press Releases